Pharmaceutical Technology

JANUARY 13, 2025

IDRxs lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal tumours.

Leads 59

Leads Patients 59

European Pharmaceutical Review

NOVEMBER 21, 2023

According to GSK, thirty-five million patients with respiratory conditions globally relying on its metered dose inhaler. Dosing of first patients is planned in the first half of 2024. However, this accounts for nearly half of GSK’s carbon footprint, and contributes to the carbon footprint of global health systems.

Manufacturing 116

Manufacturing Patients Pharma Leads 116

PM360

FEBRUARY 17, 2025

Biolumina and AstraZeneca Success May Be Fleeting Concurrent chemoradiation therapy (cCRT) can only take patients so far. The Success may be fleeting campaign aims to educate oncologists that the highest risk of progression is within 2 years following cCRT completion and that treatment advances are urgently needed.

Pharma 52

Pharma Leads Education Management 52

Legacy MEDSearch

FEBRUARY 26, 2025

tariffstargeting imports from key manufacturing hubs like China, Mexico, and Canadais set to introduce new challenges that will reshape the landscape of medical device sales and manufacturing in 2025. As a result, many manufacturers may pass increased costs onto healthcare providers, which could trickle down to patients and insurance systems.

Manufacturing 52

Manufacturing Medical Sales Healthcare Provider 52

European Pharmaceutical Review

FEBRUARY 2, 2024

The ATLab (Alpha Therapy Laboratory) Valenciennes in Onnaing, France, will produce lead-212 radioligand therapies. So construction of the new radioligand therapy manufacturing site in France is a major step towards making these promising new treatments available to cancer patients with high unmet needs.

Manufacturing 98

Manufacturing Distribution Leads Pharmaceutical 98

PM360

FEBRUARY 17, 2025

Phreesia and Colorectal Cancer Alliance No Ifs, Ands, or Buts: Point-of-Care Awareness Campaign on Colorectal Cancer Screenings Phreesia and the Colorectal Cancer Alliance partnered to promote screening for early detection of colorectal cancer & patient awareness of colorectal cancer (CRC) prevalence.

Pharma 52

Pharma Engineering Management Leads 52

European Pharmaceutical Review

OCTOBER 22, 2024

The UK is set to be the first country to introduce a new regulatory framework for innovative products manufactured at or close to the point of patient care, says the Medicines and Healthcare products Regulatory Agency (MHRA). The agency anticipated that the regulation could become law in Summer 2025.

Medicine 89

Medicine Manufacturing Safety Consulting 89

PM360

FEBRUARY 17, 2025

As patients with ALK+ NSCLC often need to choose between efficacy and quality of life, we leaned into the iconic lung shape to celebrate the harmony between treatment and life passions and the positive impact being made on patients lives.

Pharma 52

Pharma Competition Marketing Leads 52

Pharmaceutical Technology

DECEMBER 21, 2022

The vaccine manufacturing facility will also offer National Health Service (NHS) patients access to the company’s Covid-19 vaccines that can provide protection against various variants. Planned to be operational by 2025, the construction of the facility is anticipated to begin early next year.

Government 140

Government Manufacturing Pharmaceutical Marketing 140

Infuse Medical

FEBRUARY 4, 2025

billion by 2025. This creates a gap in knowledge that impacts patient outcomes and organizational efficiency. Difficulty in Mastering Complex Procedures The complexity of modern medical devices and procedures often leads to steep learning curves.

Training 130

Training Medical Healthcare Healthcare 130

PM360

FEBRUARY 17, 2025

BOEHRINGER INGELHEIM TEAM MEMBERS: Christine Sakdalan , Therapeutic Area Head, Mental Health Franchise Michael Jablonski , Vice President of Clinical Development and Medical Affairs, Mental Health Carlos de Leon , Director of Marketing, Mental Health Diane Roznowski , Director of Marketing and US Commercial Lead, Mental Health Kim Bigman , Senior Associate (..)

Pharma 52

Pharma Healthcare Provider Education Marketing 52

pharmaphorum

OCTOBER 26, 2022

The drug was highlighted at Boehringer’s R&D update earlier this year as one of the most promising candidates among 15 new medicines it plans to bring to market by 2025, fuelled by a €25 billion R&D spend. The programme will include two trials – FIBRONEER IPF and FIBRONEER-ILD – which will recruit patients across 40 countries.

Recruitment 98

Recruitment Prospecting Marketing Patients 98

pharmaphorum

SEPTEMBER 29, 2022

A digital patient monitoring tool developed by UK company CyberLiver has been given a breakthrough designation by the FDA for out-of-hospital management of patients with cirrhosis at risk of complications. The post Digital tool cuts hospital readmissions in cirrhosis patients appeared first on.

Patients 52

Patients Management Consulting FDA 52

PM360

OCTOBER 25, 2023

According to a report by McKinsey & Company, the medical affairs function is on track to rise in importance, becoming the third strategic pillar alongside the research and development (R&D) and commercial functions by 2025. This lack of understanding may lead to resistance or wariness of new technology. Regulatory concerns.

Management 105

Management Medical Pharma Pharmaceutical 105

European Pharmaceutical Review

AUGUST 1, 2022

The goal is to “ensure all patient groups are reflective of the real-world population and aligned with the epidemiology of the disease studies,” a statement said. Therefore, it is essential that we broaden the scope of medical trials and research,” commented Tinamarie Duff, DAWN Global People & Business Resource Group Lead.

Food and Drug Administration 122

Food and Drug Administration Medical Medicine Engineering 122

pharmaphorum

JANUARY 9, 2023

Supported by voting agreements from leading Amryt shareholders and directors, and unanimously approved and recommended by the boards of both companies, the total transaction is worth up to $1.48 Biopharma and healthcare group Chiesi Farmaceutici S.p.A. is to acquire the 2015-established Amryt Pharma Plc. in an all-cash transaction at $14.50

Pharma 98

Pharma Biopharma Management Medicine 98

PM360

JANUARY 7, 2025

Acquisition highlights companies shared commitment to clients, workplace culture, and attracting the industrys best people TORONTO, ON/SARATOGA SPRINGS, NY January 7, 2025 Klick Health today announced it has acquired Peregrine Market Access, a leading market access strategy and value communications specialist in life sciences.

Marketing 52

Marketing Leads Medical Consulting 52

PM360

FEBRUARY 17, 2025

As the first novel targeted therapy approved for mCRC regardless of mutation status in more than a decade, FRUZAQLA has the potential to renew optimism in HCPs who are desperate to offer their patients a chance to live longer after other treatments have failed.

Pharma 40

Pharma Management Leads Medical 40

Pharmaceutical Technology

SEPTEMBER 5, 2022

Until 2025, we have strong growth ahead of us, but we also believe we can continue to grow very strongly post-2025 and it’s all about innovation in the pipeline.”. On 23 August, at a Reuters Newsmakers online forum, Soriot announced his interest in increasing AstraZeneca’s portfolio of bolt-on acquisitions leading up to 2025.

FDA 114

FDA Pharmaceutical Biopharma Pharma 114

MaBiCo

JANUARY 21, 2025

Personalized Medicine Thanks to AI, we will create simulations of the human body at the molecular, cellular and organ levels, allowing treatments to be personalized for each patient. This will lead to treatments that are more effective and safer, as the specificities of each patient will be taken into account.

Medical science 96

Medical science Medicine Patients Management 96

European Pharmaceutical Review

FEBRUARY 4, 2025

Moderna] was the biggest industry sponsor of clinical trials in the UK in 2023/24″ The site is anticipated to be fully operational later in 2025, ready to deliver British-made COVID-19 vaccines, ensuring a robust supply for the UK public, stated Darius Hughes, General Manager of Moderna UK.

Government 71

Government Manufacturing Leads Pharmaceutical 71

Pharmaceutical Technology

APRIL 17, 2023

The proposed merger is expected to realise at least $50m of net transaction cash proceeds, set to be used to finance the merged entity’s business as well as Phase II trials and operations through the second quarter of 2025. The merger is scheduled to be completed by the third quarter of 2023.

Patients 98

Patients Leads Pharmaceutical Marketing 98

European Pharmaceutical Review

NOVEMBER 23, 2023

For example, CPI asserted that lead times for clinical trial materials are hindering new therapies being developed. The Oligonucleotide Manufacturing Innovation Centre of Excellence will also facilitate “a highly skilled workforce” to be trained and development to accelerate access of these medicines to patients, CPI noted.

Manufacturing 104

Manufacturing Medicine Government Pharmaceutical 104

Pharmaceutical Technology

JANUARY 8, 2023

Today, approximately 384 million people around the globe have COPD and it is the third leading cause of death worldwide, the Global Initiative for Chronic Obstructive Lung Disease reports. While options like bronchodilator inhalers are available for COPD patients, these have limitations. Biologics: From asthma to COPD?

Patients 119

Patients FDA Pharmaceutical Pharma 119

European Pharmaceutical Review

MARCH 14, 2024

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function.

Food and Drug Administration 98

Food and Drug Administration Patients Leads Side effects 98

European Pharmaceutical Review

MARCH 14, 2024

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function.

Food and Drug Administration 98

Food and Drug Administration Patients Leads Side effects 98

European Pharmaceutical Review

NOVEMBER 21, 2024

Dr Boshoff will begin this new role on 1 January 2025 and will oversee all R&D functions across every therapeutic area in the company. Furthermore, Dr Roger Dansey will become Interim Chief Oncology Officer, from 1 January 2025. Dr Johanna Bendell from Roche is set to be Pfizer’s Chief Development Officer, Oncology from 2025.

Medicine 59

Medicine Medical science Biopharma Medical 59

European Pharmaceutical Review

DECEMBER 3, 2024

We are excited to collaborate with Novartis to accelerate the potential of PTC518 for the hundreds of thousands of [Huntington’s disease] patients worldwide in need of a therapy designed to be well-tolerated and an effective disease-modifying therapy.

Biopharma 59

Biopharma Leads Pharmaceutical Manufacturing 59

pharmaphorum

OCTOBER 13, 2022

It is World Osteoporosis Day this month, and Ben Hargreaves takes a look at what treatment options look like for patients living with the disease. However, there is a problem facing the treatment of osteoporosis, and it is the lack of research into new therapies, leading to a limited pipeline of new treatments coming through.

Marketing 98

Marketing Healthcare Healthcare Leads 98

Clarify Health

NOVEMBER 21, 2024

According to research from PwC, medical costs alone are projected to rise 7–8% in 2025 , marking the highest increase in over 13 years. By simplifying their technology landscape, health systems can significantly optimize costs, reduce provider burnout, and enhance patient care. Following record healthcare spending of $4.5

Healthcare 52

Healthcare Healthcare Leads Medical 52

PM360

SEPTEMBER 21, 2023

This article covers some of the reasons these drugs were chosen, how the process for price negotiation will occur, and the impact for the industry and for patients. Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

pharmaphorum

AUGUST 17, 2022

The deal will see Atomwise identify, synthesize, and advance lead compounds for up to five drug targets that will then be exclusively Sanofi’s to develop. A recent report from GlobalData predicted that pharma spending on AI drug discovery would hit $3 billion in 2025.

Medicine 97

Medicine Pharma Engineering Sales 97

pharmaphorum

AUGUST 9, 2022

AI could address the most significant issue in drug discovery, finds Ben Hargreaves, and also offers the potential to use tissue samples to create precision medicine for specific patient groups. Cancer is the second leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, according to the World Health Organization.

Doctors 111

Doctors Patients Medicine Pharma 111

Infuse Medical

DECEMBER 17, 2024

Maintaining high standards of patient care in the healthcare scene of today depends on operational efficiency and exact administration of medical devices. Leading change in these processes is virtual reality (VR), which provides creative ideas for fleet management of medical equipment and operational optimization in healthcare.

Management 130

Management Healthcare Healthcare Training 130

European Pharmaceutical Review

DECEMBER 18, 2024

percent (high-dose) of patients with ulcerative colitis treated with duvakitug achieved clinical remission, Teva Pharmaceuticals and Sanofi shared. For patients with Crohns disease, at week 14, 26.1 Detailed findings of this study are set to be presented at a scientific forum in 2025, according to Sanofi and Teva.

Leads 52

Leads Pharmaceutical Medicine Patients 52

PM360

JULY 13, 2023

billion by 2025, growing at a compound annual growth rate of 6.7%. billion by 2025, growing at a compound annual growth rate of 6.7%. Solving this will require reassembling these solutions to put the patient at the center of the healthcare experience. The global healthcare IT market was valued at $280.3

Healthcare 98

Healthcare Healthcare Consulting Healthcare Provider 98

Evolve Your Success

NOVEMBER 28, 2023

Using innovative AI-assisted devices redefines treatment approaches and envisions a future where technology greatly enhances patient care. Join us as Charles explores the game-changing HiDO device , a groundbreaking technology designed to transform patient care and medication management. He goes by the name of Charles Gellman.

Medical 130

Medical Medical sales Sales Patients 130